The growth capital will be used to expand BardyDx's sales force and monitoring services, advance research and development programs, and accelerate development of artificial intelligence diagnostic capabilities.
BardyDx is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry.
The company's Carnation Ambulatory Monitor (CAM) patch is a non-invasive, P-wave centric ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for men, women, and children through its lifestyle-enabling patch design.
SV Health Investors is a healthcare and life sciences venture capital and growth equity firm that targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health.
Health Enterprise Partners invests primarily in privately held, middle market companies in health care services and health care information technology.
The company seeks to invest in companies that improve the quality of the patient experience, expand access, and reduce the cost of health care.
Ascension Ventures is a strategic healthcare venture firm that constructs and manages a strategic portfolio of investments that deliver venture-level investment returns, have the potential to transform the healthcare industry, and significantly enhance the experience for patients, their families and their caregivers.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients